Matthew P. Young is CFO & VP at Jazz Pharmaceuticals plc (JAZZ). They have made 16 open-market trades across 2 companies since 2017, most recently 2021-07-01.
CIK 0001601583
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 16 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JAZZ | SELL | 2019-03-06 | 2019-03-07 | $135.41 | $312K | +0.7% | +6.6% | -3.1% |
| JAZZ | SELL | 2019-02-26 | 2019-02-27 | $131.46 | $504K | -3.6% | +3.6% | -3.4% |
| JAZZ | SELL | 2018-11-23 | 2018-11-27 | $150.00 | $105K | -6.5% | -18.8% | -15.4% |
| JAZZ | SELL | 2018-10-15 | 2018-10-17 | $158.08 | $221K | -3.5% | -10.1% | -19.4% |
| JAZZ | SELL | 2018-09-17 | 2018-09-19 | $162.70 | $228K | +1.2% | -4.6% | -15.5% |
| JAZZ | SELL | 2018-08-15 | 2018-08-16 | $176.05 | $246K | -2.3% | -7.4% | -18.5% |
| JAZZ | SELL | 2018-07-16 | 2018-07-18 | $176.06 | $123K | -1.9% | -1.2% | -10.2% |
| JAZZ | SELL | 2018-06-15 | 2018-06-19 | $176.99 | $124K | -4.3% | -1.6% | -10.5% |
| JAZZ | SELL | 2018-06-01 | 2018-06-05 | $170.04 | $850K | +3.3% | +2.4% | -0.6% |
| JAZZ | SELL | 2018-05-15 | 2018-05-16 | $164.64 | $468K | +2.7% | +10.5% | +9.4% |
| JAZZ | SELL | 2018-04-16 | 2018-04-18 | $156.01 | $109K | -3.7% | +6.2% | +11.3% |
| JAZZ | SELL | 2018-03-15 | 2018-03-19 | $151.22 | $106K | -3.9% | +0.6% | +13.2% |
| JAZZ | SELL | 2018-03-06 | 2018-03-07 | $142.52 | $214K | +7.8% | +2.8% | +18.3% |
| JAZZ | SELL | 2018-02-27 | 2018-02-28 | $146.32 | $695K | +6.2% | +0.9% | +14.2% |
| JAZZ | SELL | 2018-01-16 | 2018-01-18 | $152.16 | $107K | +0.1% | -3.3% | +5.5% |
| PRAH | SELL | 2017-11-16 | 2017-11-17 | $79.90 | $817K | +1.8% | +10.8% | +10.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.